Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Tristetraprolin expression by keratinocytes protects against skin carcinogenesis
Assabban, Assiya , Dubois-Vedrenne, Ingrid, Maele, Laurye Van , Salcedo, Rosalba, Snyder, Brittany L. , Zhou, Lecong , Azouz, Abdulkader , Toeuf, Bérengère de de , Lapouge, Gaëlle, La, Caroline, Melchior, Maxime, Nguyen, Muriel, Thomas, Séverine , Wu, Si , Hu, Wenqian , Kruys, Véronique , Blanpain, Cédric , Hu, Wenqian , Thomas, Séverine, Trinchieri, Giorgio , Gueydan, Cyril , Blackshear, Perry J. , Goriely, Stanislas

Mayo Clinic

JCI Insight | January 26, 2021 | Volume: 6 | Issue: 5 | Pages: No page available

10.1172/jci.insight.140669 | PMID 33497366 Get It

Cancer is caused primarily by genomic alterations resulting in deregulation of gene regulatory circuits in key growth, apoptosis, or DNA repair pathways. Multiple genes associated with the initiation and development of tumors are also regulated at the level of mRNA decay, through the recruitment of RNA-binding proteins to AU-rich elements (AREs) located in their 3′-untranslated regions. One of these ARE-binding proteins, tristetraprolin (TTP; encoded by Zfp36 ), is consistently dysregulated in many human malignancies. Herein, using regulated overexpression or conditional ablation in the context of cutaneous chemical carcinogenesis, we show that TTP represents a critical regulator of skin tumorigenesis. We provide evidence that TTP controlled both tumor-associated inflammation and key oncogenic pathways in neoplastic epidermal cells. We identify Areg as a direct target of TTP in keratinocytes and show that EGFR signaling potentially contributed to exacerbated tumor formation. Finally, single-cell RNA-Seq analysis indicated that ZFP36 was downregulated in human malignant keratinocytes. We conclude that TTP expression by epidermal cells played a major role in the control of skin tumorigenesis.
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations
Venable, Elise R. , Chen, Dong , Chen, Constance P. , Bessonen, Kurt, Nguyen, Phuong L., Oliveira, Jennifer L. , Reichard, Kaaren K. , Hoyer, James D., Althoff, Simon D., Roh, Dana J., Miller, Mechelle A., Begna, Kebede H. , Patnaik, Mrinal M. , Litzow, Mark R. , Al‐Kali, Aref , Viswanatha, David S., He, Rong , Herrick, Jennifer L. , Bessonen, Kurt R, Chen, Dong

Mayo Clinic

American Journal of Clinical Pathology | January 22, 2021 | Volume: 156 | Issue: 4 | Pages: 679-690

10.1093/ajcp/aqab010 | PMID 33978189 Get It

Abstract Objectives SF3B1 mutations are the most common mutations in myelodysplastic syndromes (MDS). The International Working Group for the Prognosis of MDS (IWG-PM) recently proposed SF3B1-mutant MDS (SF3B1-mut-MDS) as a distinct disease subtype. We evaluated the spectrum and molecular landscape of SF3B1-mutated myeloid disorders and assessed the prognostication in MDS harboring SF3B1 mutations (MDS-SF3B1). Methods Cases were selected by retrospective review. Clinical course and laboratory and clinical findings were collected by chart review. SF3B1-mut-MDS was classified following IWG-PM criteria. Results SF3B1 mutations were identified in 75 of 955 patients, encompassing a full spectrum of myeloid disorders. In MDS-SF3B1, Revised International Prognostic Scoring System (IPSS-R) score greater than 3 and transcription factor (TF) comutations were adverse prognostic markers by both univariate and multivariate analyses. We confirmed the favorable outcome of IWG-PM-defined SF3B1-mut-MDS. Interestingly, it did not show sharp prognostic differentiation within MDS-SF3B1. Conclusions SF3B1 mutations occur in the full spectrum of myeloid disorders. We independently validated the favorable prognostication of IWG-PM-defined SF3B1-mut-MDS. However it may not provide sharp prognostication within MDS-SF3B1 where IPSS-R and TF comutations were prognostic-informative. Larger cohort studies are warranted to verify these findings and refine MDS-SF3B1 prognostication.
Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-blinded Randomized Controlled Trial
Lemaine, Valérie, Lohse, Christine M. , Mandrekar, Jay , Ramaker, Sheri, Convery, Phyllis A., Nguyen, Minh D. , Tran, Nho V. , Mandrekar, Jay N., Ramaker, Sheri A, Nguyen, Minh-Doan

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 13, 2021 | Volume: 8 | Issue: 8 | Pages: e3030

10.1097/gox.0000000000003030 | PMID 32983785 Get It

Background: Subpectoral tissue expander breast reconstruction is often associated with muscle spasms, pain, and discomfort during tissue expansion. In this study, we hypothesized that an intraoperative injection of botulinum toxin A (BTX-A) in the pectoralis major muscle reduces the pain associated with tissue expansion and improves women’s physical well-being. Methods: Between May 2012 and May 2017, women undergoing immediate subpectoral tissue expander breast reconstruction were randomized to administer 100 units of BTX-A or a placebo injection. A numeric pain intensity scale and the physical well-being scale of the BREAST-Q: Reconstruction Module were used to test our hypothesis. Data on postoperative oral narcotic consumption were not collected. Results: Of the 131 women included in the analysis, 48% were randomized to placebo and 52% to BTX-A. The preoperative median pain intensity score was 0 [interquartile range (IQR), 0–1], and the median preoperative BREAST-Q score was 91 (IQR, 81–100). The median slopes for the change in pain intensity scores from baseline throughout tissue expansion for those randomized to placebo and BTX-A were −0.01 (IQR, −0.02 to 0.00) and −0.01 (IQR, −0.02 to 0.00), respectively (P = 0.55). The median slopes for the change in BREAST-Q scores from baseline throughout tissue expansion for those randomized to placebo and BTX-A were 0.04 (IQR, −0.17 to 0.14) and 0.02 (IQR, −0.06 to 0.13), respectively (P = 0.89). Conclusion: In this study, we found that an intraoperative intramuscular injection of 100 units of BTX-A in the pectoralis major muscle did not reduce postoperative pain and patient-reported physical well-being when compared with placebo.
The association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study
Hubbard, Aubrey K. , Richardson, Michaela , Rosesler, Michelle A., Cioc, Adina, Nguyen, Phuong , Warlick, Erica D. , Poynter, Jenny N. , Nguyen, Phuong L.

Mayo Clinic

Leukemia & Lymphoma | January 10, 2021 | Volume: 62 | Issue: 6 | Pages: 1474-1481

10.1080/10428194.2020.1869962 | PMID 33416407 Get It

Yersinia occitanica is a later heterotypic synonym of Yersinia kristensenii subsp. rochesterensis and elevation of Yersinia kristensenii subsp. rochesterensis to species status
Nguyen, Scott V. , Cunningham, Scott A. , Jeraldo, Patricio , Tran, Anthony , Patel, Robin , Jeraldo, Patricio R , Patel, Robin , Cunningham, Scott A

Mayo Clinic

International Journal of Systematic and Evolutionary Microbiology | January 6, 2021 | Volume: 71 | Issue: 2 | Pages: No page available

10.1099/ijsem.0.004626 | PMID 33406034 Get It

The taxonomic position of Yersinia kristensenii subsp. rochesterensis and Yersinia occitanica was re-evaluated by genomic analysis. Average nucleotide identity (ANI), digital DNA–DNA hybridization values, and phylogenetic analyses of the type strains indicate that Y. kristensenii subsp. rochesterensis and Y. occitanica are the same genospecies. Additionally, the overall genomic relatedness index (OGRI) values reveal that Y. kristensenii subsp. rochesterensis should be elevated to species status as Yersinia rochesterensis sp. nov.
Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non–Hepatocellular Carcinoma Factors
Adeniji, Nia , Arjunan, Vinodhini, Prabhakar, Vijay, Ghaziani, Tahereh , Kwo, Paul Y. , Nguyen, Mindie H. , Melcher, Marc L. , Busuttil, Ronald W. , Haydel, Brandy , Ruiz, Richard , Klintmalm, Göran B. , Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Tevar, Amit D. , Humar, Abhinav , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Nydam, Trevor L. , Markmann, James F. , Mobley, Constance M. , Ghobrial, R. Mark , Langnas, Alan N. , Carney, Carol A., Berumen, Jennifer , Sudan, Debra L. , Hong, Johnny C. , Rana, Abbas , Jones, Christopher M. , Fishbein, Thomas , Dhanasekaran, Renumathy , Lee, David D , Dhanasekaran, Renumathy , Melcher, Marc L , Halazun, Karim J , Chapman, William C , Sudan, Debra L , Kwo, Paul Y , Mannalithara, Ajitha , Ahmed, Aijaz , Florman, Sander , Taner, C. Burcin , Hoteit, Maarouf , Schnickel, Gabriel T , Agopian, Vatche G.

Mayo Clinic

Liver Transplantation | December 11, 2020 | Volume: 27 | Issue: 5 | Pages: 684-698

10.1002/lt.25974 | PMID 33306254 Get It

The incidence of hepatocellular carcinoma (HCC) is growing in the United States, especially among the elderly. Older patients are increasingly receiving transplants as a result of HCC, but the impact of advancing age on long‐term posttransplant outcomes is not clear. To study this, we used data from the US Multicenter HCC Transplant Consortium of 4980 patients. We divided the patients into 4 groups by age at transplantation: 18 to 64 years (n = 4001), 65 to 69 years (n = 683), 70 to 74 years (n = 252), and ≥75 years (n = 44). There were no differences in HCC tumor stage, type of bridging locoregional therapy, or explant residual tumor between the groups. Older age was confirmed to be an independent and significant predictor of overall survival even after adjusting for demographic, etiologic, and cancer‐related factors on multivariable analysis. A dose‐response effect of age on survival was observed, with every 5‐year increase in age older than 50 years resulting in an absolute increase of 8.3% in the mortality rate. Competing risk analysis revealed that older patients experienced higher rates of non–HCC‐related mortality (P = 0.004), and not HCC‐related death (P = 0.24). To delineate the precise cause of death, we further analyzed a single‐center cohort of patients who received a transplant as a result of HCC (n = 302). Patients older than 65 years had a higher incidence of de novo cancer (18.1% versus 7.6%; P = 0.006) after transplantation and higher overall cancer‐related mortality (14.3% versus 6.6%; P = 0.03). Even carefully selected elderly patients with HCC have significantly worse posttransplant survival rates, which are mostly driven by non–HCC‐related causes. Minimizing immunosuppression and closer surveillance for de novo cancers can potentially improve the outcomes in elderly patients who received a transplant as a result of HCC.
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Lefterova, Martina I., Artyomenko, Alexander , Kasi, Pashtoon Murtaza , Mody, Kabir , Catenacci, Daniel V.T. , Fakih, Marwan , Bárbácioru, Cátálin, Zhao, Jing , Fairclough, Stephen R. , Kim, Seung Tae , Kim, Jinchul , Gavino, Danielle , Benavides, Manuel , Peled, Nir , Nguyen, Timmy, Cusnir, Mike , Eskander, Ramez N. , Azzi, Georges, Banks, Kimberly C. , Chudova, Darya, Talasaz, AmirAli , Lee, Jeeyun , Odegaard, Justin I. , Artyomenko, Alexander , Kasi, Pashtoon Murtaza , Kim, Kyoung-Mee , Kim, Jinchul , Gavino, Danielle , Benavides, Manuel , Nguyen, Timmy , Cusnir, Mike , Banks, Kimberly C , Raymond, Victoria M , Lanman, Richard B , Odegaard, Justin I , Willis, Jason A. , Nakamura, Yoshiaki , Sikora, Marcin , Lee, Hyuk , Yoshino, Takayuki , Raymond, Victoria M. , Lanman, Richard B. , Kopetz, Scott , Fakih, Marwan

Mayo Clinic

Clinical Cancer Research | December 1, 2020 | Volume: 25 | Issue: 23 | Pages: 7035-7045

10.1158/1078-0432.ccr-19-1324 | PMID 31383735 Get It

AbstractPurpose:To analytically and clinically validate microsatellite instability (MSI) detection using cell-free DNA (cfDNA) sequencing.Experimental Design:Pan-cancer MSI detection using Guardant360 was analytically validated according to established guidelines and clinically validated using 1,145 cfDNA samples for which tissue MSI status based on standard-of-care tissue testing was available. The landscape of cfDNA-based MSI across solid tumor types was investigated in a cohort of 28,459 clinical plasma samples. Clinical outcomes for 16 patients with cfDNA MSI-H gastric cancer treated with immunotherapy were evaluated.Results:cfDNA MSI evaluation was shown to have high specificity, precision, and sensitivity, with a limit of detection of 0.1% tumor content. In evaluable patients, cfDNA testing accurately detected 87% (71/82) of tissue MSI-H and 99.5% of tissue microsatellite stable (863/867) for an overall accuracy of 98.4% (934/949) and a positive predictive value of 95% (71/75). Concordance of cfDNA MSI with tissue PCR and next-generation sequencing was significantly higher than IHC. Prevalence of cfDNA MSI for major cancer types was consistent with those reported for tissue. Finally, robust clinical activity of immunotherapy treatment was seen in patients with advanced gastric cancer positive for MSI by cfDNA, with 63% (10/16) of patients achieving complete or partial remission with sustained clinical benefit.Conclusions:cfDNA-based MSI detection using Guardant360 is highly concordant with tissue-based testing, enabling highly accurate detection of MSI status concurrent with comprehensive genomic profiling and expanding access to immunotherapy for patients with advanced cancer for whom current testing practices are inadequate.See related commentary by Wang and Ajani, p. 6887
Plasma Biomarkers of Alzheimer’s Disease in African Americans
Deniz, Kaancan , Ho, Charlotte C.G. , Malphrus, Kimberly G., Reddy, Joseph S. , Nguyen, Thuy , Carnwath, Troy , Lucas, John A. , Graff‐Radford, Neill R. , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Carnwath, Troy P, Crook, Julia E. , Carrasquillo, Minerva M.

Mayo Clinic

Journal of Alzheimer's Disease | November 27, 2020 | Volume: 79 | Issue: 1 | Pages: 323-334

10.3233/jad-200828 | PMID 33252078 Get It

Background/Objective: The aim of this study was to determine if plasma concentrations of 5 surrogate markers of Alzheimer’s disease (AD) pathology and neuroinflammation are associated with disease status in African Americans. Methods: We evaluated 321 African Americans (159 AD, 162 controls) from the Florida Consortium for African-American Alzheimer’s Disease Studies (FCA3DS). Five plasma proteins reflecting AD neuropathology or inflammation (Aβ42, tau, IL6, IL10, TNFα) were tested for associations with AD, age, sex, APOE and MAPT genotypes, and for pairwise correlations. Results: Plasma tau levels were higher in AD when adjusted for biological and technical covariates. APOE ɛ4 was associated with lower plasma Aβ42 and tau levels. Older age was associated with higher plasma Aβ42, tau, and TNFα. Females had lower IL10 levels. Inflammatory proteins had strong pairwise correlations amongst themselves and with Aβ42. Conclusion: We identified effects of demographic and genetic variants on five potential plasma biomarkers in African Americans. Plasma inflammatory biomarkers and Aβ42 may reflect correlated pathologies and elevated plasma tau may be a biomarker of AD in this population.
Fine-needle aspiration of pancreatic cystic lesions: a randomized study with long-term follow-up comparing standard and flexible needles
Al‐Haddad, Mohammad , Wallace, Michael B. , Brugge, William R. , Li, Zhao-Shen, Sethi, Amrita , Pleskow, Douglas K. , Pannala, Rahul , Woodward, Timothy A., Ramchandani, Mohan , Jin, Zhendong , Xu, Can , Faigel, Douglas O. , Pleskow, Douglas , Raimondo, Massimo , Ramchandani, Mohan J , Wallace, Michael B , Al-Haddad, Mohammad , Lakhtakia, Sundeep , Li, Zhao‐Shen , Nguyen, Cuong Cao , DeWitt, John M.

Mayo Clinic

Endoscopy | November 16, 2020 | Volume: 53 | Issue: 11 | Pages: 1132-1140

10.1055/a-1311-9927 | PMID 33197941 Get It

Abstract Background Pancreatic cystic lesions (PCLs) are increasingly found on cross-sectional imaging, with the majority having a low risk for malignancy. The added value of fine-needle aspiration (FNA) in risk stratification remains unclear. We evaluated the impact of three FNA needles on diagnostic accuracy, clinical management, and the ability to accrue fluid for tumor markers. Methods A multicenter prospective trial randomized 250 patients with PCLs ≥ 13 mm 2:1:1 to 19G Flex, 19G, and 22G needles with crossover for repeated FNA procedures. Diagnostic accuracy was established at 2-year follow-up, with the final diagnosis from surgical histopathology or consensus diagnosis by experts based sequentially on clinical presentation, imaging, and aspirate analysis in blinded review. Results Enrolled patients (36 % symptomatic) had PCLs in the head (44 %), body (28 %), and tail (26 %). Percentage of cyst volume aspirated was 78 % (72 % – 84 %) for 19G Flex, 74 % (64 % – 84 %) for 22G, and 73 % (63 % – 83 %) for 19G (P = 0.84). Successful FNA was significantly higher for 19G Flex (89 % [82 % – 94 %]) and 22G (82 % [70 % – 90 %]) compared with 19G (75 % [63 % – 85 %]) (P = 0.02). Repeated FNA was required more frequently in head/uncinate lesions than in body and tail (P < 0.01). Diagnostic accuracy of the cyst aspirate was 84 % (73 % – 91 %) against histopathology at 2-year follow-up (n = 79), and 77 % (70 % – 83 %) against consensus diagnosis among nonsurgical cases (n = 171). Related serious adverse events occurred in 1.2 % (0.2 % – 3.5 %) of patients. Conclusions Our study results demonstrate a statistically significant difference among the three needles in the overall success rate for aspiration, but not in the percentage of cyst volume aspirated. Flexible needles may be particularly valuable in sampling cystic PCLs in the pancreatic head/uncinate process.
Plastic Drape and Copper Frame For Airway Management in the COVID-19 Era: A Case Series
Mainville, Darcy J., Hou, Borin, Chrissian, Ara A., Giri, Paresh C. , Chang, Melody , Turay, David, Shipley, Desara, Markovich, Susan, Scott, Loreen, Smith, Dustin D. , Dorotta, Ihab, Nguyen, H. Bryant , Mukherjee, Kaushik , Mainville, Darcy J

Mayo Clinic

No container title available | November 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-99957/v1 Get It

Abstract Purpose: Airway manipulation is a high-risk procedure due to aerosolization of viral particles. This has become of paramount importance during the COVID-19 pandemic in an effort to protect personnel involved in airway management. We designed and tested a copper frame to support a plastic drape to contain aerosols and allow for reduction of risk during airway management. The “CopperHead” frame allows airway management with minimal limitations in a wide range of scenarios including elective and urgent intubations, management of unstable patients, cardiopulmonary resuscitation (CPR), bronchoscopy, and extubation. The frame was made of copper to utilize its inherent antimicrobial and antiviral properties. Intervention and Measurements: We performed multiple simulations to measure FiO2 accumulation underneath the frame and plastic drape. We also performed defibrillations on a mannequin with the apparatus in place to evaluate for safety during times that the device is not removed prior to defibrillation, as indicated. We then deployed the device throughout our hospital and analyzed the resulting data on procedure success and infection rates in both COVID-positive and COVID-negative cohorts.Main Results: The technique is reproducible and allows for airway manipulation in COVID-19 suspected or confirmed patients. The FiO2 under the copper frame and plastic drape increased, but quickly dispersed when the frame was removed. We performed multiple defibrillations with apparatus in place with no adverse events. We showed that with the device in place, there appears to be no hindrance to successful intubation with 94 successful procedures in 74 patients and an 87% (60/69) first-pass intubation rate, and there were no documented clinicians or respiratory therapy infections through exposures to COVID-19 positive patients.Conclusions: The addition of a copper frame to a plastic drape over patients was an effective way to improve the safety and ease of intubation in the COVID-19 pandemic. This device was well received among our clinicians and served to benefit both intubation and extubation of recovered patients.